

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF WASHINGTON

CHERIE BALLEW, Individually and
on behalf of others similarly situated,

Plaintiff,

v.

MATRIX INITIATIVES, INC., a
Delaware Corporation, ZICAM, LLC,
an Arizona Limited Liability
Corporation,

Defendant.

NO. CV-07-267-RHW

**ORDER DENYING PLAINTIFF'S
MOTION FOR CLASS
CERTIFICATION**

Before the Court is Plaintiff's Motion for Class Certification (Ct. Rec.20). A hearing was held on the motion on September 17, 2008, in Spokane, Washington. Plaintiff was represented by James Danielson and Kevin Bromiley. Defendants were represented by Jeffry Thomas and Alan Lazarus.

BACKGROUND FACTS

On July 19, 2007, Plaintiff filed a putative class action suit on behalf of all Washington consumers in Superior Court in Chelan County, alleging that users of Zicam, a homeopathic, over-the-counter cough/cold remedy, lost their smell and/or taste. In her complaint, Plaintiff asserts claims under the Washington Consumer Protection Act and Washington Products Liability Act. Plaintiff is seeking punitive, treble and other damages, reasonable attorneys' fees, and a permanent injunction against Defendants enjoining Defendants from engaging in unfair and deceptive business acts in the state of Washington.

**ORDER DENYING PLAINTIFF'S MOTION FOR CLASS
CERTIFICATION ~ 1**

1 Defendants removed the action on August 17, 2007, citing federal diversity
2 jurisdiction.

3 Plaintiff now moves for certification of the class and proposes the following
4 class:

5
6 All individuals who used defendants' Zicam cold remedy product(s)
7 and thereafter suffered any loss of the sense of smell and/or taste since
8 July 17, 2003.

9 DISCUSSION

10 A. Standard of Review

11 The parties disagree as to the standard of review that the Court must impose.
12 Plaintiff argues that the Court must take Plaintiff's allegations as true, and that a
13 discussion of the merits of the allegations is inappropriate in deciding a motion for
14 class certification. Relying on *Eisen v. Carlisle & Jacquelin*, 417 U.S. 156 (1974),
15 Plaintiff argues that clear case law prohibits the Court from conducting "a
16 preliminary inquiry into the merits of a suit in order to determine whether it may be
17 maintained as a class action", relying on *Eisen v. Carlisle and Jacquelin*, 417 U.S.
18 156 (1974). Defendants argue that the Court must conduct a "rigorous analysis,"
19 relying on *General Tel. Co. of Southwest v. Falcon*, 457 U.S. 147 (1982).

20 While it is true the Court should not expand the Rule 23 certification
21 analysis to include consideration of whether the proposed class is likely to prevail
22 ultimately on the merits, Ninth Circuit precedent has instructed that the Court
23 should not accept the plaintiffs' allegations for purposes of certifying a class in this
24 case. *Gareity v. Grant Thornton, LLP*, 368 F.3d 356 (9th Cir. 2004).

25 In *Gareity*, the Circuit concluded that the district court erred in that:

26 by accepting the plaintiffs' allegations for purposes of certifying
27 a class in this case, the district court failed to comply adequately with
28 the procedural requirements of Rule 23. Rule 23(b)(3) on its face
requires the court to "find [] that the questions of law or fact common
to the members of the class predominate over any questions affecting

only individual members....” (Emphasis added). In addition, the Rule lists numerous factors for the court to consider in making its “findings.” If it were appropriate for a court simply to accept the allegations of a complaint at face value in making class action findings, every complaint asserting the requirements of Rule 23(a) and (b) would automatically lead to a certification order, frustrating the district court’s responsibilities for taking a “close look” at relevant matters, *Amchem*, 521 U.S. at 615, 117 S.Ct. 2231, for conducting a “rigorous analysis” of such matters, *Falcon*, 457 U.S. at 161, 102 S.Ct. 2364, and for making “findings” that the requirements of Rule 23 have been satisfied, see Fed.R.Civ.P. 23(b)(3). Moreover, if courts could only consider the pleadings, then “parties would have wide latitude to inject frivolous issues to bolster or undermine a finding of predominance.” Robert G. Bone & David S. Evans, *Class Certification and the Substantive Merits*, 51 Duke L.J. 1251, 1269 (2002).

Id. at 365.

The Circuit went on to conclude that while an evaluation of the merits to determine the strength of Plaintiff’s case is not part of the Rule 23 analysis, the factors spelled out in Rule 23 must be addressed through findings, even if they overlap with issues on the merits and observed:

We must not lose sight of the fact that when a district court considers whether to certify a class action, it performs the public function of determining whether the representative parties should be allowed to prosecute the claims of absent class members. Were the court to defer to the representative parties on this responsibility by merely accepting their assertions, the court would be defaulting on the important responsibility conferred on the courts by Rule 23 of carefully determining the class action issues and supervising the conduct of any class action certified.

Id. at 366-67.

It is true that at this stage of the proceedings the Court is not resolving whether Plaintiff can establish that she can prove her case. Rather, the narrow question before the Court is whether, under Fed. R. Civ. P. 23, a class action is a proper vehicle for litigating the products liability claims brought by Plaintiff.

B. Fed. R. Civ. P. 23 Requirements

Fed. R. Civ. P. 23 sets forth the requirements to a class action. Fed. R. Civ. P. 23(a) states:

One or more members of a class may sue or be sued as representative parties on behalf of all only if (1) the class is so numerous that joinder of all members is impracticable; (2) there are

1 questions of law or fact common to the class; (3) the claims or
 2 defenses of the representative parties are typical of the claims or
 3 defenses of the class; and (4) the representative parties will fairly and
 4 adequately protect the interest of the class.

5 Plaintiff bears the burden of demonstrating that she has met each of the four
 6 requirements of Rule 23(a) and at least one of the requirements of Rule 23(b).
 7 *Lozano v. AT&T Wireless Serv., Inc.*, 504 F.3d 718, 724 (9th Cir. 2007).

8 Plaintiff seeks certification under Rule 23(b)(1), (2), and (3). Thus, in
 9 addition to finding that the prerequisites are met, the Court must also find that
 10 either:

11 (1) prosecuting separate actions by or against individual class
 12 members would create a risk of:

13 (A) inconsistent or varying adjudications with respect to
 14 individual class members that would establish incompatible
 15 standards of conduct for the party opposing the class; or
 16 (B) adjudications with respect to individual class members that,
 17 as a practical matter, would be dispositive of the interests of the
 18 other members not parties to the individual adjudications or
 19 would substantially impair or impede their ability to protect
 20 their interests;

21 (2) the party opposing the class has acted or refused to act on grounds
 22 that apply generally to the class, so that final injunctive relief or
 23 corresponding declaratory relief is appropriate respecting the class as
 24 a whole; or

25 (3) the court finds that the questions of law or fact common to class
 26 members predominate over any questions affecting only individual
 27 members, and that a class action is superior to other available methods
 28 for fairly and efficiently adjudicating the controversy.
 Fed. R. Civ. P. 23(b).

29 **C. Plaintiff's Allegation**

30 At oral argument, Plaintiff indicated that the common question or issue that
 31 she seeks to certify the class on is whether zinc gluconate can cause loss of smell
 32 and taste in humans. Under this theory, the dosage, frequency of use, method of
 33 application, and the medical history of the user does not come into play with
 34 respect to class certification. Nor, according to Plaintiff, does it matter which

1 product was used.¹

2 The Court should not to certify a class based on this broad, abstract question.
3 *See Sprague v. General Motors Corp.*, 133 F.3d 388, 397 (6th Cir. 1998) (“[I]t is
4 not every common question that will suffice, however; at a sufficiently abstract
5 level of generalization, almost any set of claims can be said to display
6 commonality.”).

7 Here, this issue as framed by Plaintiff does not apply specifically to
8 Defendants in that it could apply to any manufacturer who uses zinc gluconate.
9 Nor is it tied to Defendants’ conduct. Answering this question resolves no class
10 member’s claim and only invites the difficult question of how to proceed once the
11 question is answered. Little, if any time or effort will be saved by answering this
12 question in the abstract. Hypothetically, if this question were presented to the jury
13 and it did, in fact, find that zinc gluconate could cause loss of smell and taste in
14 humans, this finding would basically be useless, unless it was tied to Defendants’
15 method and manner of using zinc gluconate, which, as the Court understands,
16 Plaintiff does not intend to do in the first phase of litigation.

17 A crude analogy would be the common question of whether salt can cause
18 high blood pressure. A jury finding of yes lends no help to a class action based on
19 any particular product containing salt. Individual questions of dosage, medical
20

21 ¹There are five Zicam Cold Remedy Products—three taken orally (an oral
22 mist, a chewable, and a rapidmelt); and two nasal gels (one applied with a swab
23 which is smeared just inside the nostril, and the other is applied to the lower nasal
24 cavity with a metered pump). With respect to the metered pump, there are two
25 types of pump. The first generation pump (G1) was used between 1999 and 2005
26 and it expelled gel through a single hole actuator nozzle. The second generation
27 pump (G2) replaced the G1 and it uses a multi-holed actuator called the
28 showerhead.

1 condition, method of ingestion, etc. would predominate.

2 Plaintiff's attempt to frame the issue in general, abstract terms does not solve
3 the problems of certification that are inherent in a products liability suit, namely,
4 that individual issues predominate over common questions of law or fact.

5 Although the Ninth Circuit has rejected a *per se* rule that would create an absolute
6 bar to class certification for products liability cases based on drugs or medical
7 devices, *see Valentino v. Carter-Wallace, Inc.*, 97 F.3d 1227, 1230 (9th Cir. 1996),
8 the Circuit has recognized that there are potential difficulties of "commonality"
9 and "management" inherent in certifying products liability class actions. *Zinser v.*
10 *Accufix Research Instit.*, 253 F.3d 1180, 1186 (9th Cir. 2001). The Court notes that
11 many courts presiding over similar products liability cases involving prescription
12 drugs have denied requests for class certification.²

13
14 ²*See In re Aredia and Zometa Prods. Liab. Litig.*, 06-MD-1760, 2007 WL
15 3012972 (M.D. Tenn. Oct.10, 2007) (users of intravenous-bisphosphonate drugs
16 seeking dental monitoring for ONJ); *In re Vioxx Prods. Liab. Litig.*, 239 F.R.D.
17 450 (E.D. La. 2006) (recalled prescription pain medication); *In re Prempro Prods.*
18 *Liab. Litig.*, 230 F.R.D. 555 (E.D. Ark. 2005) (menopause drug); *Foster v. St. Jude*
19 *Medical, Inc.*, 229 F.R.D. 599, 604-05 (D.C. Minn. 2005) (heart bypass device);
20 *Zehel-Miller v. Astrazenaca Pharmaceuticals, LP*, 223 F.R.D. 659, 663 (M.D. Fla.
21 2004) (depression drug); *In re Baycol Prods. Litig.*, 218 F.R.D. 197 (D. Minn.
22 2003) (recalled cholesterol drug); *Perez v. Metabolife Int'l, Inc.*, 218 F.R.D. 262
23 (S.D. Fla. 2003) (recalled over-the-counter dietary supplement); *In re Paxil*, 212
24 F.R.D. 539 (C.D. Cal. 2003) (drug prescribed to treat depression, anxiety and other
25 disorders); *In re Rezulin Prods. Liab. Litig.*, 210 F.R.D. 61 (S.D.N.Y. 2002)
26 (recalled diabetes drug); *In re Propulsid Prods. Liab. Litig.*, 208 F.R.D. 133, 147,
27 (E.D. La. 2002) (GERD drug); *Foister v. Purdue*, No. 01-268-DCR, 2002 WL
28 1008608 (E.D. Ky., February 26, 2002) (denying certification of an OxyContin

1 Even if the Court were to accept that Plaintiff's framing of the common
2 question or issue is appropriate, however, Plaintiff has failed to meet the
3 requirements of Fed. R. Civ. P. 23 for class certification.

4 **D. Analysis**

5 **1. Fed. R. Civ. P. 23(a)**

6 **a. Numerosity**

7 In her motion in support of class certification, Plaintiff relies on estimates of
8 the volume of Zican cold remedy products that Matrixx distributes to Washington
9 state to argue that the joinder of all potential defendant class members is
10 impossible. Plaintiff also provided a document that indicates that between 2004
11 and 2006, Matrixx received 690 complaints from customers who suffered loss of
12 smell and/or taste after using Zicam cold remedy products. Plaintiff also suggests
13 that, based on the fact that Arizona and Washington have nearly identical
14 populations, it can be estimated that approximately 360 individuals in Washington
15 have claims against Matrixx for loss of sense of smell and/or taste. At oral
16 argument, Plaintiff argued that evidence suggests that there were 35 Washington
17 residents that filed complaints in 2006-07.

18 The Court finds that this suggested methodology of determining whether it is
19 impractical to join potential plaintiffs is speculative and unreliable and not
20 sufficient to meet Plaintiff's burden under Fed. R. Civ. P. 23(a).

21
22
23 class), *Gevedon v. Purdue Pharma*, 212 F.R.D. 333 (E.D. Ky. 2002) (denying
24 certification of an OxyContin class); *In re Phenylpropanolamine ("PPA") Products*
25 *Liability Litigation*, 208 F.R.D. 625 (W.D. Wash. 2002); *but see In re Diet Drugs*
26 *Prods. Liab. Litig.*, 1999 WL 673066 (E.D. Pa. Aug. 26, 1999) (conditionally
27 certifying class of diet drug users); *In re Teletronics Pacing Systems, Inc.*, 172
28 F.R.D. 271 (S.D. Ohio 1997) (certifying class of pacemaker recipients).

1 **b. Commonality**

2 Plaintiff must show that there are questions of law or fact common to the
3 class. Fed. R. Civ. P. 23(a)(2). Commonality focuses on the relationship of
4 common facts and legal issues among class members. *Dukes v. Wal-Mart*, 509
5 F.3d 1168, 1177 (9th Cir. 2007). “The existence of shared legal issues with
6 divergent factual predicates is sufficient, as is the common core of salient facts
7 coupled with disparate legal remedies within the class. *Hanlon v. Chrysler Corp.*,
8 150 F.3d 1011, 1019 (9th Cir. 1998). “The commonality test is qualitative rather
9 than quantitative—one significant issue common to the class may be sufficient to
10 warrant certification.” *Dukes*, 509 F.3d at 1177.

11 As discussed above, Plaintiff asserts that the common question is whether
12 zinc gluconate can cause loss of smell and taste in humans. On one level, this
13 meets the commonality requirement, which arguable has been construed
14 permissively. *See Hanlon*, 150 F.3d at 1019. However, the Court has not found
15 any case law that found that commonality is met by asserting such a broad, abstract
16 common question, and for the reasons stated above, the Court declines to do so in
17 this case.

18 **c. Typicality**

19 Plaintiff must show that “the claims or defenses of the representative parties
20 be typical of the claims or defenses of the class.” Fed. R. Civ. P. 23(a)(3).
21 “[R]epresentative claims are ‘typical’ if they are reasonably co-extensive with
22 those of absent class members; they need not be substantially identical.” *Hanlon*,
23 150 F.3d at 1020. “Typicality requires that the named plaintiffs be members of the
24 class they represent. *Dukes*, 509 F.3d at 1184. The question the Court must
25 determine, then, is whether the injury allegedly suffered by Plaintiff and the rest of
26 the class resulted from the same alleged conduct. *Id.*

27 As discussed above, Plaintiff attempts to get around the typicality
28 requirement by framing the common question in broad, generalized terms.

1 However, the reality is that Plaintiff's claim, based on her use of the G2 applicator,
 2 is not typical of potential class members who may have used a different type of
 3 applicator or one of the other Zicam products.

4 **d. Fairly and Adequately Represent Parties**

5 Rule 23(a)(4) permits certification of a class action only if "the
 6 representative parties will fairly and adequately protect the interests of the class."
 7 Fed. R. Civ. P. 23(a)(4). This factor requires: (1) that the proposed representative
 8 plaintiff does not have conflicts of interest with the proposed class, and (2) that the
 9 plaintiff is represented by qualified and competent counsel. *Hanlon*, 150 F.3d at
 10 1020. "[A] class representative must be part of the class and 'possess the same
 11 interest and suffer the same injury' as the class members." *Amchem Products, Inc.*
 12 *v. Windsor*, 521 U.S. 591, 626 (1997) (citations omitted).

13 Here, Plaintiff has met the requirement that she is represented by qualified
 14 and competent counsel, however, she cannot show that she would not have
 15 conflicts of interest with members of the proposed class, specifically, those that
 16 used the G1 nasal spray applicator.

17 **e. Conclusion**

18 The Court finds that Plaintiff has not established numerosity, commonality,
 19 and typicality. As such, her motion for class certification fails. For the sake of
 20 completeness, the Court will also address whether Plaintiff can meet Rule 23(b)
 21 requirements.

22 **2. Fed. R. Civ. P. 23(b)(1)**

23 (1) prosecuting separate actions by or against individual class
 24 members would create a risk of:
 25 (A) inconsistent or varying adjudications with respect to
 26 individual class members that would establish
 27 incompatible standards of conduct for the party opposing
 28 the class; or
 (B) adjudications with respect to individual class
 members that, as a practical matter, would be dispositive
 of the interests of the other members not parties to the
 individual adjudications or would substantially impair or
 impede their ability to protect their interests;

1 There are two separate provisions under Rule 23(b)(1).³ Plaintiff does not
 2 indicate under which provision she is seeking certification, but in her motion
 3 asserts that this condition is met because bringing these claims as a class will
 4 prevent inconsistent decisions.

5 With respect to a claim under Fed. R. Civ. P. 23(b)(1)(A), the phrase
 6 “incompatible standards of conduct” refers to the situation where “different results
 7 in separate actions would impair the opposing party’s ability to pursue a uniform
 8 continuing course of conduct.” *Zinser*, 253 F.3d at 1193. Rule 23(b)(1)(A)
 9 certification requires more “than a risk that separate judgments would oblige the
 10 opposing party to pay damages to some class members but not to others or to pay
 11 them different amounts . . .” *Id.* Certification under 23(b)(1)(A) is not appropriate
 12 in an action for damages. *Id.*

13 Here, the Court does not find that Rule 23(b)(1) certification would be
 14 appropriate. If Plaintiff brings an individual products liability suit and others bring
 15 individual products liability suits, Defendant will not be hampered in its ability to
 16 pursue a uniform continuing course of conduct, because the liability for each of the
 17 individual suits will be based on individual issues. Moreover, Plaintiff’s claims are
 18 primarily for damages, including treble and punitive damages.

19 **3. Fed. R. Civ. P. 23(b)(2)**

20 (2) the party opposing the class had acted or refused to act on grounds
 21 that apply generally to the class, so that final injunctive relief or
 22 corresponding declaratory relief is appropriate respecting the class as
 a whole.

23 Class certification under Rule 23(b)(2) is appropriate only where the primary
 24 relief sought is declaratory or injunctive. *Zinser*, 253 F.3d at 1195.

25 _____
 26 ³Certification pursuant to Rule 23(b)(1)(B) is justified where the case
 27 involves a “fund” with a definitely ascertained limit. *Id.* Plaintiff has not argued
 28 that there is a limited fund in this case.

1 Here, the primary relief sought is damages, not declaratory or injunctive
 2 relief.⁴ Thus, Plaintiff has not met her burden of meeting the requirements of Fed.
 3 R. Civ. P. 23(b)(2).

4 **4. Fed. R. Civ. P.23(b)(3)**

5 (3) the court finds that the questions of law or fact common to class
 6 members predominate over any questions affecting only individual
 7 members, and that a class action is superior to other available methods
 8 for fairly and efficiently adjudicating the controversy. The matters
 9 pertinent to these findings include:

- 10 (A) the interest of members of the class in individually
- 11 controlling the prosecution or defense of separate actions;
- 12 (B) the extent and nature of any litigation concerning the
- 13 controversy already commenced by or against members
- 14 of the class;
- 15 (C) the desirability or undesirability of concentrating the
- 16 litigation of the claims in the particular forum;
- 17 (D) the difficulties likely to be encountered in the
- 18 management of the class action.

13 In order to meet Rule 23(b)(3) requirements, Plaintiff must show both
 14 predominance and superiority of a class action claim. In order to satisfy the
 15 predominance test, Plaintiff must show that the adjudication of common issues will
 16 help achieve judicial economy. *Zinser*, 253 F.3d at 1189. In considering
 17 superiority, courts must consider the four factors of Rule 23(b)(3) while focusing
 18 on the efficiency and economy elements of the class actions. *Id.* Where damages
 19 suffered by each putative class member are not large, this factor weighs in favor of
 20 certifying a class action. *Id.* at 1190.

21 Here, the Court finds that the individual issues involving dosage, frequency
 22 of use, method of application, and the medical history of the user predominate over
 23 the common issue of whether zinc gluconate can cause loss of taste or smell in
 24 humans. Nor does it appear that a class action suit is a superior method to other

25
 26 ⁴In her complaint, Plaintiff indicates that she is seeking a permanent
 27 injunction against Defendants enjoining Defendants from engaging in unfair and
 28 deceptive business acts in the state of Washington.

1 available methods for fairly and efficiently adjudicated products liability claims
2 based on the use of Zicam. Numerous individuals have brought suit to separately
3 adjudicate their claims, including the twenty-one Washington plaintiffs who
4 commenced and resolved litigation in Arizona state court. *Id.* (“[T]he existence of
5 litigation indicates that some of the interested parties have decided that individual
6 actions are an acceptable way to proceed, and even may consider them preferable
7 to a class action.”). Defendants report that a total of 92 suits have been filed to
8 date.

9 **E. Conclusion**

10 Plaintiff has failed to meet the requirements of Fed. R. Civ. P. 23(a) and (b).
11 Therefore, class certification is not appropriate.

12 Accordingly, **IT IS HEREBY ORDERED:**

13 1. Plaintiff’s Motion for Class Certification (Ct. Rec. 20) is **DENIED**.

14 **IT IS SO ORDERED.** The District Court Executive is directed to enter this
15 Order and forward copies to counsel.

16 **DATED** this 31st day of October, 2008.

17 *S/ Robert H. Whaley*

18 **ROBERT H. WHALEY**
19 Chief United States District Judge
20
21
22

23 Q:\CIVIL\2007\Ballew\deny.cert.wpd
24
25
26
27
28